Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,716 | 295 | 1,404 |
| Samples | 766 | 182 | 575 |
| Peptides | 591 | 126 | 490 |
Function
CACNA2D3 · Calcium voltage-gated channel auxiliary subunit alpha2delta 3
This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. Research on a highly similar protein in rabbit suggests the protein described in this record is cleaved into alpha-2 and delta subunits. Alternate transcriptional splice variants of this gene have been observed but have not been thoroughly characterized. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 565 amino-acid changes on canonical ENST00000474759 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CACNA2D3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CACNA2D3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| Melanoma | 29/210 14% | 191/1899 10% |
| Acute Myeloid Leukemia | 9/90 10% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 10/42 24% | 32/612 5% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Hodgkins Lymphoma | 3/16 19% | 2/122 2% |
| Non-Small Cell Lung Carcinoma | 19/304 6% | 38/1390 3% |
| Colorectal Carcinoma | 26/143 18% | 72/3239 2% |
| Gastric Carcinoma | 0/74 0% | 40/1809 2% |
| Germ Cell Tumour | 3/25 12% | 1/169 1% |
| Other Solid Cancers | 6/94 6% | 25/1515 2% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 11/810 1% |
| Hepatocellular Carcinoma | 1/46 2% | 29/2210 1% |
| Cervical Carcinoma | 2/35 6% | 4/422 1% |
| Esophageal Carcinoma | 0/23 0% | 10/769 1% |
| Other Sarcomas | 4/69 6% | 4/699 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Breast Carcinoma | 12/144 8% | 19/3264 1% |
| Ovarian Carcinoma | 5/109 5% | 5/998 0% |
| Bladder Carcinoma | 1/58 2% | 8/956 1% |
| Non-Cancerous | 0/104 0% | 8/830 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Biliary Tract Carcinoma | 1/54 2% | 7/950 1% |
| Glioma | 1/52 2% | 16/2127 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| B-Cell Non-Hodgkins Lymphoma | 6/88 7% | 13/2534 1% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Pancreatic Carcinoma | 3/89 3% | 5/1611 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
Mutation Distribution
Where CACNA2D3 is mutated · all tissues, split by cell line vs tissue
How many mutations in CACNA2D3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,716 mutations in CACNA2D3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|